Endocrine withdrawal syndromes

被引:120
作者
Hochberg, Z
Pacak, K
Chrousos, GP
机构
[1] NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA
[2] Meyer Childrens Hosp, Div Endocrinol, IL-31096 Haifa, Israel
关键词
D O I
10.1210/er.2001-0014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypersecretion of endogenous hormones or chronic administration of high doses of the same hormones induces varying degrees of tolerance and dependence. Elimination of hormone hypersecretion or discontinuation of hormone therapy may result in a mixed picture of two syndromes: a typical hormone deficiency syndrome and a generic withdrawal syndrome. Thus, hormones with completely different physiological effects may produce similar withdrawal syndromes, with symptoms and signs reminiscent of those observed with drugs of abuse, suggesting shared mechanisms. This review postulates a unified endocrine withdrawal syndrome, with changes in the hypothalamic-pituitary-adrenal axis and the central opioid peptide, in which noradrenergic and dopaminergic systems of the brain act as common links in its pathogenesis. Long-term adaptations to hormones may involve relatively persistent changes in molecular switches, including common intracellular signaling systems, from membrane receptors to transcription factors. The goals of therapy are to ease withdrawal symptoms and to expedite weaning of the patient from the hormonal excess state. Clinicians should resort to the fundamentals of tapering hormones down over time, even in the case of abrupt removal of a hormone-producing tumor. In addition, the prevention of stress and concurrent administration of antidepressants may ameliorate symptoms and signs of an endocrine withdrawal syndrome.
引用
收藏
页码:523 / 538
页数:16
相关论文
共 169 条
[1]   Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results [J].
Abosch, A ;
Tyrrell, JB ;
Lamborn, KR ;
Hannegan, LT ;
Applebury, CB ;
Wilson, CB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3411-3418
[2]   ANDROGENIC-ANABOLIC STEROID EFFECTS ON SERUM THYROID, PITUITARY AND STEROID-HORMONES IN ATHLETES [J].
ALEN, M ;
RAHKILA, P ;
REINILA, M ;
VIHKO, R .
AMERICAN JOURNAL OF SPORTS MEDICINE, 1987, 15 (04) :357-361
[3]   ANABOLIC-STEROID WITHDRAWAL DEPRESSION - A CASE-REPORT [J].
ALLNUTT, S ;
CHAIMOWITZ, G .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1994, 39 (05) :317-318
[4]   CERTAIN ENDOCRINE AND METABOLIC FACETS OF STEROID WITHDRAWAL SYNDROME [J].
AMATRUDA, TT ;
HURST, MM ;
DESOPO, ND .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1965, 25 (09) :1207-+
[5]   STUDY OF THE MECHANISM OF THE STEROID WITHDRAWAL SYNDROME - EVIDENCE FOR INTEGRITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL SYSTEM [J].
AMATRUDA, TT ;
HOLLINGSWORTH, DR ;
DESOPO, ND ;
UPTON, GV ;
BONDY, PK .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1960, 20 (03) :339-354
[6]   EFFECT OF INESCAPABLE SHOCK ON SUBSEQUENT ESCAPE PERFORMANCE - CATECHOLAMINERGIC AND CHOLINERGIC MEDIATION OF RESPONSE INITIATION AND MAINTENANCE [J].
ANISMAN, H ;
REMINGTON, G ;
SKLAR, LS .
PSYCHOPHARMACOLOGY, 1979, 61 (02) :107-124
[7]  
AXELROD L, 1990, PRINCIPLES PRACTICE
[8]   Absence of catch-down growth in Russell-Silver syndrome after short-term growth hormone treatment [J].
Azcona, C ;
Stanhope, R .
HORMONE RESEARCH, 1999, 51 (01) :47-49
[9]  
BACKSTROM T, 1976, ACTA NEUROL SCAND, V54, P321
[10]   DOPAMINE AUTORECEPTOR AGONISTS IN THE TREATMENT OF SCHIZOPHRENIA AND MAJOR DEPRESSION [J].
BENKERT, O ;
GRUNDER, G ;
WETZEL, H .
PHARMACOPSYCHIATRY, 1992, 25 (06) :254-260